Company Overview of GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company develops lead product rivipansel, a glycomimetic drug candidate that has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. It also develops GMI-1271, a specific E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers; and GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a ...
401 Professional Drive
Gaithersburg, MD 20879
Founded in 2003
Key Executives for GlycoMimetics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $417.0K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $285.4K
Chief Medical Officer and Vice President of Clinical Development
Total Annual Compensation: $345.0K
Chief Scientific Officer, Vice President of Research and Director
Total Annual Compensation: $309.8K
Compensation as of Fiscal Year 2014.
GlycoMimetics, Inc. Key Developments
GlycoMimetics Announces Initiation of Phase 3 Clinical Trial Assessing the Efficacy and Safety of Rivipansel for the Treatment of Vaso-Occlusive
Jun 24 15
GlycoMimetics announced the initiation of a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in patients hospitalized with sickle cell disease in partnership with Pfizer Inc. The dosing of the first patient under this Phase 3 clinical trial has triggered the second of two milestone payments from Pfizer to GlycoMimetics totaling USD 35 million. Under the partnership, Pfizer dosed the first patient in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study, which is a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for treating vaso-occlusive crisis in patients hospitalized with sickle cell disease who are six years of age or older. In conjunction with the trial, the primary endpoint for the study will be time to readiness-for-discharge. Key secondary endpoints will include time to discharge, cumulative IV opioid consumption and time to discontinuation of IV opioids. Sickle cell disease is a genetic disease affecting people in the US, predominantly of African descent. One of the most severe complications of sickle cell disease is vaso-occlusive crisis, which is typically characterized by excruciating, debilitating pain that occurs periodically throughout the life of a person with sickle cell disease.
GlycoMimetics, Inc., Annual General Meeting, Jul 15, 2015
Jun 15 15
GlycoMimetics, Inc., Annual General Meeting, Jul 15, 2015., at 10:00 US Eastern Standard Time. Location: 9714 Medical Center Drive. Agenda: To elect the two nominees for director named herein to hold office until the 2018 annual meeting of stockholders; to ratify the selection by the audit committee of the board of directors of Ernst & Young LLP as the independent registered public accounting firm for its fiscal year ending December 31, 2015; and to conduct any other business properly brought before the meeting.
GlycoMimetics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:00 AM
Jun 11 15
GlycoMimetics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:00 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Armand Girard, Vice President of Corporate Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|